MedPath

Diagnosis of Cardiac Amyloidosis With 99mTc-PYP; Comparison Between Planar Imaging, SPECT/CT and Cardiac-dedicated CZT Camera

Not Applicable
Conditions
Cardiac Amyloidosis
Interventions
Diagnostic Test: Spect scan with mTc99-PYP
Registration Number
NCT04146415
Lead Sponsor
Tel-Aviv Sourasky Medical Center
Brief Summary

1. Patients will undergo clinical and laboratory assessment, as well as imaging tests, at the discretion of the attending cardiologist and will be referred at their discretion to perform cardiac mapping using 99mTc-PYP.

2. On the day of the examination, the examiner will be admitted to the Office of Nuclear Medicine and will be admitted to administrative. Before conducting the test, the subject will undergo a brief interview by a physician, receive an explanation of the study and, if agreed, sign an agreement to perform a further examination on the CZT camera.

3. The patient will, as is customary, be installed on Vanflon 22 G periphery, through which a 15 millikiric (mCi) of

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
30
Inclusion Criteria

A. Patients undergoing "cardiac amyloidosis clinic" at Tel Aviv Medical Center and there is a clinical suspicion of having cardiac amyloidosis.

B. Patients who performed will be referred for mapping using 99mTc-PYP and sign a consent form to take another photograph, under the cardiac-dedicated CZT camera

Exclusion Criteria

1.None

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Cardiac amyloidosis patientsSpect scan with mTc99-PYP-
Primary Outcome Measures
NameTimeMethod
Patients who preformed mTc99-PYP for cardiac amyloidosis imaging.1 year

Evaluation of cardiac amyloidosis imaging with mTc99-PYP cardiac-dedicated CZT camera

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath